Juan M. Bustamante

Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease.

CD8+ T cells in Trypanosoma cruzi infection.

In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Methodological advances in drug discovery for Chagas disease.

Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence.

Long-Term Immunity to Trypanosoma cruzi in the Absence of Immunodominant trans-Sialidase-Specific CD8+ T Cells.

Rapid, Selection-Free, High-Efficiency Genome Editing in Protozoan Parasites Using CRISPR-Cas9 Ribonucleoproteins.

Trypanosoma cruzi 13C-labeled O-Glycan standards for mass spectrometry.

Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases.

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease.

Identification of Growth Inhibitors with Activity In Vivo within a Collection of Licensed Drugs.